CA-XSOLLA
16.7.2024 14:01:35 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the launch of Xsolla Backend, an innovative solution designed to help developers of all sizes, especially indie and midsize teams, work across various gaming platforms. Xsolla Backend makes their games more accessible by allowing developers to unite their audience across all platforms: PC, console, mobile, and the web. This addresses audience fragmentation common to most games and enables developers to save costs while creating deeper engagement as they grow their gaming business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716151058/en/
(Graphic: Xsolla)
Xsolla Backend offers developers a scalable and affordable solution to enhance game functionality and player engagement across all technology platforms. This includes streamlined account management, efficient matchmaking, dynamic questing systems, and robust cross-play and multiplayer functionalities. These features ensure a more connected and immersive gaming experience, allowing developers to focus more on the creative aspects of game development while minimizing technical complexities. The vertically integrated solution enables cross-play and cross-pay across all platforms, seamlessly integrated with Xsolla game commerce solutions.
Jean-Philippe Steinmetz, Head of Xsolla Backend, states, "With Xsolla Backend, we are democratizing backend technology, ensuring developers of all sizes can access advanced tools needed to create compelling, immersive gaming experiences."
Following the strategic acquisition of the award-winning AcceleratXR technology in 2023, Xsolla Backend is designed to handle the majority of game backend needs from the outset while providing developers the flexibility to customize as needed. The platform operates on a no-upfront fee model, charging only a 5% royalty, including backend hosting, making it financially accessible and beneficial for developers of all sizes.
With over 30 active partners and more than ten in-development projects, Xsolla Backend is proving to be a game-changer in the industry. Developers interested in experiencing Xsolla Backend firsthand can demo the platform at Gamescom in Cologne this August.
David Stelzer, President of Xsolla, highlights, "Our business model and robust platform design align our success with that of our partners. Xsolla Backend is not just technology but a partnership that grows with developers, supported by ongoing enhancements and a roadmap filled with powerful updates."
Later this year, Xsolla Backend will introduce new SDKs for platforms like Microsoft Xbox and Sony PlayStation, enhancing our support for major gaming systems. The expansion will also include a self-service portal, social launcher, and updates to the admin console for more efficient game management. Developers can also look forward to integrating Xsolla Payment Systems, all of which will comply with industry regulations and maintain Xsolla's standard of regulatory adherence. Additional updates will feature a party system, gameplay collectibles, tournament systems, loot boxes, and multiplayer voice chat, further enriching the gaming experience while ensuring compliance.
For more information about Xsolla Backend or to sign up, visit xsolla.pro/xbe and Discord: xsolla.pro/xbe-discord
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716151058/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom